CL2021002437A1 - Métodos para tratar la distrofia muscular con casimersin - Google Patents

Métodos para tratar la distrofia muscular con casimersin

Info

Publication number
CL2021002437A1
CL2021002437A1 CL2021002437A CL2021002437A CL2021002437A1 CL 2021002437 A1 CL2021002437 A1 CL 2021002437A1 CL 2021002437 A CL2021002437 A CL 2021002437A CL 2021002437 A CL2021002437 A CL 2021002437A CL 2021002437 A1 CL2021002437 A1 CL 2021002437A1
Authority
CL
Chile
Prior art keywords
muscular dystrophy
methods
casimersin
treating muscular
treating
Prior art date
Application number
CL2021002437A
Other languages
English (en)
Inventor
Edward M Kaye
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of CL2021002437A1 publication Critical patent/CL2021002437A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona, entre otras cosas, composiciones y métodos mejorados para tratar la distrofia muscular. Por ejemplo, la descripción proporciona métodos para tratar pacientes con distrofia muscular de Duchenne que tienen una mutación en el gen DMD que es susceptible a la omisión del exón 45 por la administración de una cantidad efectiva de casimersen.
CL2021002437A 2019-03-28 2021-09-20 Métodos para tratar la distrofia muscular con casimersin CL2021002437A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825573P 2019-03-28 2019-03-28
US201962902518P 2019-09-19 2019-09-19

Publications (1)

Publication Number Publication Date
CL2021002437A1 true CL2021002437A1 (es) 2022-05-06

Family

ID=70286009

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002437A CL2021002437A1 (es) 2019-03-28 2021-09-20 Métodos para tratar la distrofia muscular con casimersin

Country Status (15)

Country Link
US (1) US20220152086A1 (es)
EP (1) EP3946376A1 (es)
JP (1) JP2022526763A (es)
KR (1) KR20210145192A (es)
CN (1) CN113660939A (es)
AU (1) AU2020244803A1 (es)
BR (1) BR112021018801A2 (es)
CA (1) CA3134165A1 (es)
CL (1) CL2021002437A1 (es)
CO (1) CO2021014024A2 (es)
IL (1) IL286653A (es)
MA (1) MA55515A (es)
MX (1) MX2021011498A (es)
SG (1) SG11202108757XA (es)
WO (1) WO2020198268A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021025899A1 (en) * 2019-08-02 2021-02-11 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer pharmaceutical compositions
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
EP0639582B1 (en) 1985-03-15 1998-09-16 Antivirals Inc. Polynucleotide assay reagent and method
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP1251170A3 (en) 1992-07-17 2002-10-30 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of NF-kappaB dependent animal diseases
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
WO1999042091A2 (en) 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
US7070807B2 (en) 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
AU2281201A (en) 1999-12-29 2001-07-09 A. James Mixson Histidine copolymer and methods for using same
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
MX2018016052A (es) * 2016-06-30 2019-05-02 Sarepta Therapeutics Inc Oligomeros de omision de exon para distrofia muscular.
EP4122497B1 (en) * 2016-12-19 2024-04-10 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
US20210145852A1 (en) * 2017-09-28 2021-05-20 Sarepta Therapeutics, Inc. Combination Therapies for Treating Muscular Dystrophy

Also Published As

Publication number Publication date
CO2021014024A2 (es) 2021-10-29
MA55515A (fr) 2022-02-09
IL286653A (en) 2021-10-31
EP3946376A1 (en) 2022-02-09
US20220152086A1 (en) 2022-05-19
BR112021018801A2 (pt) 2021-11-23
AU2020244803A1 (en) 2021-11-18
JP2022526763A (ja) 2022-05-26
CN113660939A (zh) 2021-11-16
KR20210145192A (ko) 2021-12-01
MX2021011498A (es) 2022-01-04
SG11202108757XA (en) 2021-10-28
WO2020198268A1 (en) 2020-10-01
CA3134165A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
CO2020004034A2 (es) Métodos para el tratamiento de distrofia muscular
BR112018006445A2 (pt) métodos para tratar distrofia muscular
CL2021002437A1 (es) Métodos para tratar la distrofia muscular con casimersin
CY1125083T1 (el) Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου
ECSP19043254A (es) Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2
CO2018003168A2 (es) Moduladores de la expresión de kras
CO2019006292A2 (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
BR112022007677A2 (pt) L-asparaginase recombinante
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
NZ631289A (en) Improved compositions for treating muscular dystrophy
CL2018001996A1 (es) Composiciones y métodos para modular la expresión del factor b del complemento (divisional de solicitud 2764-16)
CL2015002641A1 (es) Método para el tratamiento de la enfermedad de parkinson.
JOP20200156A1 (ar) إيسكيتامين لعلاج الاكتئاب
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
CO2021002691A2 (es) Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1)
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112022019932A2 (pt) Composições para saúde metabólica
AR122352A1 (es) Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este
CO2021007006A2 (es) Moduladores de la expresión de irf5
BR112017015613A2 (pt) gel intestinal de levodopa e carbidopa e métodos de utilização
AR118495A1 (es) Métodos para tratar la distrofia muscular
CL2023002914A1 (es) Dosificación y administración de l-asparaginasa recombinante
CO2020015685A2 (es) Composición que comprende el oligonucleótido antisentido y su uso para el tratamiento de la distrofia muscular de duchenne
CO2019014212A2 (es) Métodos de tratamiento para la distonía cervical listado de secuencias